Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors

Trial Profile

Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Oct 2015

At a glance

  • Drugs Anti-EGFR CAR-transduced T cells (Primary)
  • Indications Colorectal cancer; Liver metastases; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Sep 2015 Planned number of patients changed from 10 to 60, according to ClinicalTrials.gov record.
    • 28 Sep 2015 Results at the 5th World Congress on Cancer Therapy, according to a Cellular Biomedicine Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top